broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K26026438-001-01-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.215941 | 0.471349 | -0.024455 | 1 | 0.345235 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000921 |
BRD-K26657438-001-15-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.947786 | 0.022969 | -0.008959 | 0.973757 | 0.049705 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000921 |
BRD-K28822270-001-03-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | -0.011639 | 0.613688 | 0.508205 | 0.755253 | 1.525896 | 1.469738 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000921 |
BRD-K29905972-001-06-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.72931 | -0.523442 | -0.071737 | 0.961602 | 0.000693 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000921 |
BRD-K30577245-001-05-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.176497 | 1.975117 | 0.766192 | 0.660616 | 0.011452 | 0.014277 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000921 |
BRD-K31698212-001-02-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.136368 | -0.022038 | -0.006984 | 1 | 0.061166 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000921 |
BRD-K31928526-001-02-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.268197 | 3.061309 | 0.304346 | 1 | 0.072605 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000921 |
BRD-K33379087-001-07-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.089138 | 1.816696 | 0.702821 | 0.786312 | 1.035363 | 1.153538 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000921 |
BRD-K33610132-001-02-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.116007 | 0.060667 | -0.016244 | 1 | 0.000173 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000921 |
BRD-K33622447-066-01-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.300045 | 3.014804 | 0.422037 | 0.924202 | 3.546389 | 4.806339 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000921 |
BRD-K35520305-001-16-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.31521 | 1.947551 | 0.137465 | 1 | 4.211771 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000921 |
BRD-K36627727-001-05-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.100259 | 3.829872 | 0.154215 | 1 | 0.126272 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000921 |
BRD-K36788280-001-01-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.628059 | -1.912794 | 0.061347 | 0.978947 | 0.000844 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000921 |
BRD-K37379014-001-02-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.233006 | 4.515381 | 0.608744 | 0.767771 | 0.008262 | 0.009493 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000921 |
BRD-K38332599-001-01-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.158128 | 4.940242 | 0.68175 | 0.869914 | 2.23257 | 2.411185 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000921 |
BRD-K38527262-300-01-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.522107 | 0.178136 | -0.021092 | 1 | 154.270915 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000921 |
BRD-K38852836-001-02-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.116238 | 1.456737 | 0.878222 | 0.565708 | 0.02126 | 0.025494 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000921 |
BRD-K39974922-001-04-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.227212 | 2.479423 | -0.070073 | 1 | 0.022421 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000921 |
BRD-K41859756-001-06-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.224148 | 1.023827 | 0.697861 | 0.514907 | 0.005677 | 0.010149 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000921 |
BRD-K42828737-001-03-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.067558 | 0.030152 | -0.003535 | 1 | 0.000022 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000921 |
BRD-K42898655-001-01-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.775748 | 0.66312 | 0.141829 | 0.865098 | 0.001666 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000921 |
BRD-K43389675-001-02-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.049056 | 3.022332 | 0.693426 | 0.77759 | 1.033741 | 1.06967 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000921 |
BRD-K44227013-001-06-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | -0.020773 | 5.696547 | 0.549135 | 0.965569 | 7.424608 | 7.371883 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000921 |
BRD-K44408410-001-17-6 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.062466 | 4.527376 | 0.536288 | 0.966439 | 7.437622 | 7.66025 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000921 |
BRD-K44827188-001-06-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.877505 | 0.304486 | 0.080532 | 0.933874 | 0.042178 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000921 |
BRD-K46386702-001-02-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.917556 | -1.892626 | -0.144094 | 0.955582 | 0.113782 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000921 |
BRD-K49328571-001-15-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.339893 | 5.403498 | 0.346951 | 1 | 0.077061 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000921 |
BRD-K50010139-001-01-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.570695 | 0.180818 | -0.175227 | 1 | 19.151586 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000921 |
BRD-K50168500-001-07-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.121484 | 0.100589 | -0.067815 | 1 | 9,703.987862 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000921 |
BRD-K51313569-001-07-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.702101 | 0.340244 | 0.232832 | 0.877778 | 0.285266 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000921 |
BRD-K51791723-003-01-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.105059 | 5.025172 | 0.76559 | 0.738411 | 0.586226 | 0.614401 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000921 |
BRD-K51967704-001-03-6 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.170807 | 1.267171 | 0.793802 | 0.711064 | 0.343572 | 0.477817 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000921 |
BRD-K52313696-001-12-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.72237 | 1.245482 | 0.201268 | 0.884045 | 0.174439 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000921 |
BRD-K53414658-001-08-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.980554 | 0.228385 | -0.053141 | 0.988782 | 0.017559 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000921 |
BRD-K53972329-001-07-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.298698 | 0.573436 | 0.058672 | 1 | 1.210608 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000921 |
BRD-K54256913-001-08-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.134157 | 3.7041 | 0.778147 | 0.755278 | 0.643831 | 0.700488 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000921 |
BRD-K54955827-001-02-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.913857 | -0.001316 | -0.061696 | 0.955263 | 2,708,033,183,658,621,700,000,000 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000921 |
BRD-K54997624-001-06-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.471599 | 0.457049 | 0.152646 | 1 | 1.3522 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000921 |
BRD-K55187425-236-05-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.129746 | 5.767171 | 0.819858 | 0.600496 | 0.116196 | 0.122409 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000921 |
BRD-K56343971-001-14-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.69825 | 2.298702 | 0.341218 | 0.916595 | 0.684611 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000921 |
BRD-K56981171-001-02-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.829191 | -0.78136 | 0.127088 | 0.948361 | 0.010072 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000921 |
BRD-K57080016-001-15-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.611587 | 1.334597 | 0.062765 | 0.828751 | 0.138874 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000921 |
BRD-K57169635-001-04-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | -0.672024 | 3.432442 | 0.655449 | 0.963533 | 9.810605 | 7.65436 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000921 |
BRD-K58435339-001-03-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.21412 | 0.898677 | 0.833024 | 0.619394 | 0.091312 | 0.170096 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000921 |
BRD-K58529924-001-01-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.730401 | 1.318191 | 0.236974 | 0.920167 | 0.609098 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000921 |
BRD-K58550667-001-08-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.37837 | 6.156528 | 0.602995 | 0.889755 | 0.111781 | 0.140633 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000921 |
BRD-K59317601-001-05-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.787907 | 3.828488 | 0.24749 | 0.932293 | 0.451367 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000921 |
BRD-K59369769-001-22-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.092861 | -0.081722 | -0.145283 | 1 | 4,222.785736 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000921 |
BRD-K60997853-001-02-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.612712 | 0.357998 | -0.02066 | 1 | 38.657378 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000921 |
BRD-K61192372-001-08-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.762227 | -2.927467 | 0.126135 | 0.792693 | 2.910135 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000921 |
BRD-K62008436-001-23-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.146644 | 1.645534 | 0.616114 | 0.677091 | 0.015906 | 0.019641 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000921 |
BRD-K62196610-001-01-6 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.364123 | 0.387927 | 0.047033 | 1 | 0.016117 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000921 |
BRD-K62200014-003-10-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.063319 | 2.376326 | 0.120963 | 1 | 0.019975 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000921 |
BRD-K62391742-001-09-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.129852 | -0.514251 | -0.05669 | 1 | 0.010103 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000921 |
BRD-K62627508-001-01-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.13762 | 0.003287 | -0.003446 | 1 | 0.009455 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000921 |
BRD-K63504947-001-14-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.5135 | 0.492867 | 0.394827 | 1 | 0.230176 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000921 |
BRD-K63712959-001-01-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.947771 | 0.125493 | -0.060478 | 0.972134 | 0.025919 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000921 |
BRD-K64052750-001-22-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.342658 | 0.554691 | 0.274845 | 1 | 0.430612 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000921 |
BRD-K64881305-001-03-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.357536 | 2.652506 | 0.546272 | 0.552879 | 0.011661 | 0.01872 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000921 |
BRD-K66175015-001-12-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | -0.430738 | 2.865971 | 0.568611 | 0.949193 | 8.335583 | 6.710824 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000921 |
BRD-K67844266-003-01-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.326553 | 2.569078 | 0.355081 | 0.542278 | 0.013657 | 0.020622 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000921 |
BRD-K69001009-001-02-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.970634 | 0.078558 | -0.019302 | 0.985819 | 0.188571 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000921 |
BRD-K69694239-001-02-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.157495 | 7.131179 | 0.752782 | 0.760136 | 0.631056 | 0.665438 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000921 |
BRD-K69776681-001-03-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.458174 | 1.688129 | 0.311644 | 0.71263 | 0.058154 | 0.252857 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000921 |
BRD-K70301465-001-05-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.175471 | -0.081093 | 0.002454 | 1 | 278,087.63412 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000921 |
BRD-K70401845-001-15-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.073663 | -0.166419 | -0.012565 | 1 | 0.623188 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000921 |
BRD-K73838513-003-05-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.408314 | 1.652532 | 0.158745 | 0.947208 | 4.963207 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000921 |
BRD-K74514084-003-09-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.694127 | 3.405563 | 0.354439 | 0.905087 | 0.492241 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000921 |
BRD-K75009076-001-02-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.126998 | 4.196729 | 0.776937 | 0.728944 | 0.491359 | 0.526894 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000921 |
BRD-K76210423-001-01-6 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.028373 | -0.050147 | -0.033049 | 1 | 0.276707 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000921 |
BRD-K76239644-001-02-6 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.300472 | 0.807229 | 0.129903 | 1 | 0.232413 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000921 |
BRD-K76674262-001-03-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.064764 | 1.151139 | 0.798384 | 0.686093 | 0.392758 | 0.443059 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000921 |
BRD-K76908866-001-07-6 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.979645 | 0.032182 | -0.024747 | 0.98878 | 0.00013 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000921 |
BRD-K77625799-001-07-7 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.677421 | -1.082382 | 0.065593 | 0.925845 | 0.005209 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000921 |
BRD-K79254416-001-21-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.999371 | 0.045243 | -0.019731 | 0.999628 | 0.000022 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000921 |
BRD-K81016934-001-02-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.283649 | 0.009893 | 0.003541 | 1 | 1.318586 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000921 |
BRD-K81418486-001-44-2 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.327129 | 0.735396 | 0.253445 | 0.807012 | 0.739924 | 3.136148 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000921 |
BRD-K81473043-001-19-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.202301 | 1.595354 | 0.776682 | 0.744261 | 0.027957 | 0.038694 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000921 |
BRD-K82135108-001-04-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.366738 | 1.100098 | 0.647737 | 0.683141 | 0.077827 | 0.258908 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000921 |
BRD-K82746043-001-19-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.872771 | 0.135856 | 0.000551 | 0.924504 | 0.004379 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000921 |
BRD-K82818427-001-04-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.035567 | -0.146335 | -0.003656 | 1 | 5.018535 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000921 |
BRD-K83029223-001-01-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.314763 | 5.480879 | 0.687738 | 0.688377 | 0.007569 | 0.009073 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000921 |
BRD-K83988098-001-02-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.145492 | 1.217809 | 0.59466 | 0.746401 | 0.008977 | 0.011906 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000921 |
BRD-K85402309-043-01-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | -1.628136 | 2.688362 | 0.399946 | 0.961716 | 13.323575 | 7.773831 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000921 |
BRD-K86118762-001-01-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.009409 | -0.255122 | -0.077345 | 1 | 4.40575 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000921 |
BRD-K86972824-001-01-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.04651 | -0.038659 | -0.008233 | 1 | 2.232117 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000921 |
BRD-K87737963-001-06-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.080633 | -0.094878 | -0.007322 | 1 | 45.947348 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000921 |
BRD-K87782578-001-01-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.280311 | 0.652698 | 0.251772 | 1 | 0.237998 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000921 |
BRD-K87909389-003-03-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.103319 | 1.771303 | 0.704742 | 0.645131 | 0.214917 | 0.244924 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000921 |
BRD-K88510285-001-17-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | -0.025284 | 0.558222 | 0.409623 | 0.577756 | 0.052288 | 0.047865 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000921 |
BRD-K89014967-001-04-3 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.797425 | 0.265656 | 0.015378 | 0.912032 | 0.241583 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000921 |
BRD-K92441787-001-04-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.879163 | -3.538748 | 0.118495 | 0.897414 | 2.312686 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000921 |
BRD-K92723993-001-17-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.441643 | 2.168076 | 0.156312 | 1 | 6.09139 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000921 |
BRD-K95142244-001-01-5 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 0.357099 | 1.595567 | 0.709708 | 0.835436 | 0.844082 | 1.850497 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000921 |
BRD-K96123349-236-02-8 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.61152 | 5.601203 | 0.622981 | 1 | 0.263876 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000921 |
BRD-K98572433-001-02-9 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.495462 | 0.681833 | 0.548286 | 1 | 0.353078 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000921 |
BRD-K99113996-001-02-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.262275 | -0.101225 | -0.059989 | 1 | 0.000364 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000921 |
BRD-K99616396-001-05-1 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.241494 | 0.072329 | 0.0025 | 1 | 0.032277 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000921 |
BRD-K99749624-001-07-0 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.061153 | 0.084716 | 0.001909 | 1 | 0.001694 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000921 |
BRD-M97302542-001-04-4 | ACH-000921 | NCIH1339_LUNG | MTS010 | 1 | 1.18143 | -1.475115 | 0.005849 | 1 | 0.566983 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000921 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.